Skip to main content
MedPathMedPath Home
Clinical Trials/2023-508112-35-00
2023-508112-35-00
Recruiting
Phase 2

A phase II study assessing safety and efficacy of REPotrectinib in ROS1-positive non-small cell lung cancer patients with active brain mEtastasis (The REPOSE study)

Medica Scientia Innovation Research S.L., Medical University Of Vienna23 sites in 3 countries20 target enrollmentStarted: November 12, 2024Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 2
Status
Recruiting
Sponsor
Medica Scientia Innovation Research S.L., Medical University Of Vienna
Enrollment
20
Locations
23
Primary Endpoint
IC-ORR at any timepoint as judged by best central nervous system (CNS) response according to the Response assessment in neuro-oncology brain metastases (RANO-BM) criteria.
OverviewEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Overview

Brief Summary

To assess the efficacy in terms of intracranial objective response rate (IC-ORR).

Eligibility Criteria

Ages
18 years to 65+ years (18-64 Years, 65+ Years)
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Patient must be capable to understand the purpose of the study and have signed written informed consent form (ICF) prior to beginning specific protocol procedures.
  • •ECOG PS of ≤
  • •Minimum life expectancy of ≥ 6 weeks at screening.
  • •No limit in number of prior chemotherapies, immunotherapy or other non-ROS1 TKI regimens.
  • •Patients must not have previously received any ROS1 TKI-based treatment.
  • •Left ventricular ejection fraction (LVEF) ≥ 50% by echocardiogram (ECHO) or multigated acquisition (MUGA) scan
  • •If feasible, archival tumor biopsy sample at baseline (from primary tissue or any metastatic site) should be provided.
  • •Patient has adequate bone marrow, liver, and renal function: I. Hematological (without platelet, red blood cell transfusion, and/or granulocyte colonystimulating factor support within 7 days before first study treatment dose): White blood cell (WBC) count > 3.0 x 109/L, absolute neutrophil count (ANC) ≥ 1.5 x 109/L, platelet count ≥ 100.0 x109/L, and hemoglobin ≥ 8.0 g/dL (≥ 4.96 mmol/L).
  • •Patient has adequate bone marrow, liver, and renal function: II. Hepatic: Total bilirubin ≤ 1.5 times upper limit of normal (ULN) (≤ 3 in patients with liver metastases or know history of Gilbert’s disease); alkaline phosphatase (ALP) ≤ 2.5 times ULN; aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 times ULN (≤ 5 in patients with liver metastases); international normalized ratio (INR) < 1.
  • •Patient has adequate bone marrow, liver, and renal function: III. Renal: serum creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 40 mL/min/1.73 m2 based on Cockcroft−Gault glomerular filtration rate estimation for patients with creatinine levels above institutional normal.

Exclusion Criteria

  • •Major surgery within four weeks of the start of treatment.
  • •History of extensive, disseminated, bilateral, or presence of NCI CTCAE grade 3 or 4 interstitial fibrosis or interstitial lung disease (ILD) including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, ILD, obliterative bronchiolitis, and pulmonary fibrosis. Patients with a history of prior radiation pneumonitis are not excluded.
  • •Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or that may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study or could compromise the protocol objectives in the opinion of the Investigator.
  • •Presence or history of any other primary malignancy other than NSCLC within 5 years prior to enrollment into the study. Note: Patients with a history of adequately treated basal or squamous cell carcinoma of the skin or any adequately treated in situ carcinoma may be included in the study
  • •Current use or anticipated need for drugs that are known to be strong Cytochrome P450, family 3, subfamily A (CYP3A) inhibitors or inducers. Note: midazolam requires diligent monitoring in situations where there is an unprecedented necessity for co-administration. These cases should be discussed with the study’s medical monitor.
  • •Patients requiring concomitant use of chronic systemic (intravenously [IV] or oral) corticosteroids at doses higher than 8 mg dexamethasone per day or other immunosuppressive medications except for managing adverse events (AEs); (inhaled steroids or intra articular steroid injections are permitted in this study). Note: The use of stable corticosteroid therapy in patients with brain metastases should be discussed with the Sponsor’s Medical Monitor.
  • •Type I leptomeningeal disease per ESMO-EANO guidelines.
  • •Mean resting corrected QT interval (ECG interval measured from the onset of the QRS complex to the end of the T wave) for heart rate (QTc) > 470 msec obtained from 3 ECGs, using the screening clinic ECG machine-derived QTc value.
  • •Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block, PR interval > 250 msec).
  • •Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or any concomitant medication known to prolong the QT interval.

Outcomes

Primary Outcomes

IC-ORR at any timepoint as judged by best central nervous system (CNS) response according to the Response assessment in neuro-oncology brain metastases (RANO-BM) criteria.

IC-ORR at any timepoint as judged by best central nervous system (CNS) response according to the Response assessment in neuro-oncology brain metastases (RANO-BM) criteria.

Secondary Outcomes

  • PFS, defined as the period from treatment initiation to the first occurrence of disease progression or death from any cause, whichever occurs first, as determined locally by the investigator using RECIST v.1.1.
  • OS, defined as the period from treatment initiation to death from any cause, as determined locally by the investigator.
  • EC-ORR, defined as the rate of patients with complete response (CR) or partial response (PR), as determined locally by the investigator using RECIST v.1.1.
  • CBR, defined as the rate of patients with objective response (CR or PR), or stable disease for at least 24 weeks, as determined locally by the investigator using RECIST v.1.1.
  • DCR, defined as the percentage of patients with advanced cancer whose therapeutic intervention has led to a complete response, partial response, or stable disease.
  • TTR, defined as the period from treatment initiation to the first objective tumor response (tumor shrinkage of ≥ 30%) observed for patients who achieved a CR or PR, as determined locally by the investigator using RECIST v.1.1.
  • DoR, defined as the period from the first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first, as determined locally by the investigator using RECIST v.1.1.
  • Best percentage of change in tumor burden (RANOBM) for intracranial lesions 3 and RECIST v.1.1 for extracranial and overall lesions (bicompartmental ORR).
  • Safety endpoints: Changes from baseline in the EORTC QLQ-C30 and EORTC QLQ-BN20 scales, and symptoms scores.
  • Safety endpoints: Neurological function assessment as per NANO scale.
  • Safety endpoints: Safety and tolerability as per NCI-CTCAE v.5.0.
  • Exploratory endpoints: Exploratory endpoints can include (but are not limited to): Relationship of treatment efficacy outcomes in all patients with biomarkers analyzed in blood samples.
  • Exploratory endpoints Exploratory endpoints can include (but are not limited to): Association of efficacy outcomes in all patients with radiological imaging biomarkers.
  • Exploratory endpoints Exploratory endpoints can include (but are not limited to): Efficacy endpoints for all patients according to ROS1 gene expression level at baseline.

Investigators

Sponsor
Medica Scientia Innovation Research S.L., Medical University Of Vienna
Sponsor Class
Pharmaceutical company, Educational Institution
Responsible Party
Principal Investigator
Principal Investigator

Alicia García Sanz

Scientific

Medica Scientia Innovation Research S.L.

Study Sites (23)

Loading locations...

Similar Trials

Completed
Not Applicable
This is a study to evaluate dose-flexibility of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis
2023-504869-23-00AbbVie Deutschland GmbH & Co. KG272
Recruiting
Phase 1
A Phase IB Study to determine efficacy and safety of Durvalumab and/or novel anti-cancer agents, with or without chemotherapy, in patients with previously untreated NSCLC
2024-511956-42-00AstraZeneca AB44
Recruiting
Phase 1
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
NCT07261631Novartis Pharmaceuticals180
Not yet recruiting
Phase 2
Study that aims to investigate how effective and safe the use of a novel modified release tablet formulation of Colesevelam hydrochloride-MMX is for patients with idiopathic bile acid diarrhoea (BAD), randomly allocated to 2 different dose regimens of the active product or to the inactive placebo formulation.
2024-511993-55-00Cosmo Technologies Limited120
Recruiting
Phase 2
Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)
NCT07265570InSilico Medicine Hong Kong Limited80